The current obesity pandemic, which is in part a consequence of social trends toward higher energy intake and reduced energy expenditure, is expected to result in type 2 diabetes (T2DM) and considerable downstream morbidity, mortality and incremental costs to healthcare systems around the world [1] . The number of T2DM cases is increasing at a worrisome rate and is expected to double within the next 20 years. However, the molecular mechanisms that underlie individual changes in the predisposition to obesity and T2DM remain obscure.
The identification of DNA variants influencing disease predisposition will deliver clues to the processes involved in disease pathogenesis. This would not only spur translational innovation but also provide opportunities for personalized medicine through stratification according to an individual's risk and more precise classification of the disease subtype. Linkage analysis and largescale association studies have revealed many loci that confer susceptibility to T2DM [2, 3] .
Because microRNAs (miRNAs) have been shown to be another layer of gene regulation, it is not surprising that they are also involved in the development of obesity-induced insulin resistance and T2DM [4] . miRNAs are endogenous, single-stranded, small, ~22-nucleotide noncoding RNAs. miRNAs are generally regarded as negative regulators of gene expression by inhibiting translation and/or promoting mRNA degradation by base pairing to complementary sequences within the 3′ untranslated region (3′UTR) of protein-coding mRNA transcripts [5] . However, recent studies have suggested that miRNA-binding sites are also located in 5′UTRs or open reading frames (ORFs), and the mechanism(s) of miRNA-mediated regulation from these sites has not been defined [6, 7] . The first miRNA assigned to a specific function in metabolism was identified in Drosophila melanogaster, where loss of miRNA (miR)-14 increases body fat content [8] . Since then, a variety of miRNAs have been discovered in the regulation of glucose and lipid metabolism [9] [10] [11] [12] . The fact that T2DM susceptibility genes discovered by whole-genome association studies were located in noncoding regions supports the possibility that noncoding RNAs, such as miRNAs, may also contribute to the development of obesity and T2DM [13, 14] .
In order to understand the function of miRNAs in obesity and T2DM, the Brüning's group searched for miRNAs upregulated in liver, which were associated with specific feeding conditions [15] . Upregulation of miR-143 was also confirmed in the liver of db/db mice and diet-induced obese mice. miR-143 and miR-145 form a small gene cluster on mouse chromosome 18 and miR-145 was also upregulated in the liver and pancreas of obese mice, whereas the pattern of regulation differs in other tissues, including white and black adipose tissue.
To investigate whether increased hepatic miR-143 expression contributes to the metabolic phenotype arising from obesity in vivo, Jordan and colleagues [15] showed conditional overexpression of miR-143, predominantly in liver and brown adipose tissue, there was no change in body weight, fat mass or circulating plasma leptin concentrations. However, overexpression of miR-143 did result in a dysregulation of glucose metabolism. DOX-treated miR-143 DOX mice exhibited impaired glucose and insulin tolerance without any change in β-cell function.
To further investigate the molecular basis of insulin resistance in miR-143-DOX mice, the authors analyzed insulinstimulated signaling in liver and skeletal muscle. Conditional miR-143 overexpression impairs insulin-stimulated AKT activation in the liver but not in skeletal muscle.
To confirm the involvement of miR-143 in insulin resistance and inhibition of insulin-stimulated AKT activation, npg the authors investigated whether miR-143 deficiency can protect against obesity-induced insulin resistance in vivo. miR-143-145-deficient and control mice were exposed to high-fat feeding, and glucose metabolism and hepatic insulin signaling were compared in these mice. Both glucose tolerance and insulin sensitivity were significantly improved in obese miR-143-145-deficient mice compared with controls. Insulin sensitivity was paralleled by increased insulin-stimulated phosphorylation of AKT in the liver of obese miR-143--145-deficient mice compared with controls, which was consistent with the results from conditional miR-143 overexpression.
The recent work of Jordan and colleagues represents an important breakthrough in the determination of the molecular target of miR-143 by employing in vivo stable isotope labeling of amino This study showed increased hepatic miR-143 expression in two different obesity mouse models and demonstrated that it affects hepatic insulin action and systemic glucose homeostasis in vivo by overexpression and knockout mouse models. The present study further provides evidence for miR-143-ORP8-dependent regulation of AKT signaling in obesity (Figure 1) , and thus it is now time to examine miR-143, ORP8, and their regulated molecules as future therapeutic targets for obesity-associated insulin resistance and diabetes. 
